- Home
- ELVN vs COGT Comparison
ELVN vs COGT Comparison
Compare ELVN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- COGT
- Stock Information
- Founded
- ELVN 2016
- COGT 2014
- Country
- ELVN United States
- COGT United States
- Employees
- ELVN N/A
- COGT N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- COGT Health Care
- Exchange
- ELVN Nasdaq
- COGT Nasdaq
- Market Cap
- ELVN 1.2B
- COGT 1.1B
- IPO Year
- ELVN 2020
- COGT 2018
- Fundamental
- Price
- ELVN $20.22
- COGT $12.28
- Analyst Decision
- ELVN Strong Buy
- COGT Strong Buy
- Analyst Count
- ELVN 5
- COGT 9
- Target Price
- ELVN $41.20
- COGT $20.25
- AVG Volume (30 Days)
- ELVN 335.0K
- COGT 1.4M
- Earning Date
- ELVN 08-13-2025
- COGT 08-05-2025
- Dividend Yield
- ELVN N/A
- COGT N/A
- EPS Growth
- ELVN N/A
- COGT N/A
- EPS
- ELVN N/A
- COGT N/A
- Revenue
- ELVN N/A
- COGT N/A
- Revenue This Year
- ELVN N/A
- COGT N/A
- Revenue Next Year
- ELVN N/A
- COGT N/A
- P/E Ratio
- ELVN N/A
- COGT N/A
- Revenue Growth
- ELVN N/A
- COGT N/A
- 52 Week Low
- ELVN $13.30
- COGT $3.72
- 52 Week High
- ELVN $30.03
- COGT $12.97
- Technical
- Relative Strength Index (RSI)
- ELVN 49.43
- COGT 59.18
- Support Level
- ELVN $19.30
- COGT $11.53
- Resistance Level
- ELVN $20.28
- COGT $12.10
- Average True Range (ATR)
- ELVN 1.19
- COGT 0.48
- MACD
- ELVN 0.15
- COGT -0.08
- Stochastic Oscillator
- ELVN 59.11
- COGT 78.21
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.